A
Anders Björklund
Researcher at Lund University
Publications - 771
Citations - 87172
Anders Björklund is an academic researcher from Lund University. The author has contributed to research in topics: Transplantation & Dopamine. The author has an hindex of 165, co-authored 769 publications receiving 84268 citations. Previous affiliations of Anders Björklund include University of Washington & Institute for the Study of Labor.
Papers
More filters
Posted Content
The Economics of Unemployment Insurance: The Case of Sweden
Anders Björklund,Bertil Holmlund +1 more
Journal ArticleDOI
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
TL;DR: An alternative double-lesion paradigm is developed using injections of 6-OHDA into striatum in combination with intraventricular injections of a powerful NA immunotoxin, anti-DBH-Saporin, to eliminate the NA neurons in the locus coeruleus, and associated pontine nuclei to provide support for the view that the development of motor symptoms and dyskinetic side effects in PD patients reflects the combined loss of midbrain DA neurons and NA neurons.
Journal ArticleDOI
Basic neural transplantation techniques. I. Dissociated cell suspension grafts of embryonic ventral mesencephalon in the adult rat brain
TL;DR: The methods of preparing a dissociated cell suspension of embryonic rat substantia nigra and its transplantation into the brain of adult rats are described, paving the way for neural transplantation techniques in the mammalian central nervous system.
Journal ArticleDOI
Extracellular γ-aminobutyric acid levels in the rat caudate-putamen : monitoring the neuronal and glial contribution by intracerebral microdialysis
TL;DR: The results indicate that the extracellular GABA levels recorded by intracerebral microdialysis in the rat caudate-putamen are derived predominantly from neuronal sources.
Journal ArticleDOI
mTOR Inhibition Alleviates L-DOPA-Induced Dyskinesia in Parkinsonian Rats
TL;DR: Systemic delivery of CCI-779 prevented the development of LID and significantly alleviated the severity of dyskinesia in L-DOPA-primed animals, associated with a reduced activation of the mTOR pathway in striatal medium spiny neurons.